CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: September 25, 2012
Result type: Reports
Project Number: SR0288-000
Product Line: Reimbursement Review

Generic Name: Apixaban

Brand Name: Eliquis

Manufacturer: Bristol-Myers Squibb Canada and Pfizer Canada Inc. Alliance

Therapeutic Area: Thromboembolic events prevention, (atrial fibrillation)

Indications: Thromboembolic events prevention, (atrial fibrillation)

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: March 20, 2013

Recommendation Type: List with clinical criteria and/or conditions